58 related articles for article (PubMed ID: 24327544)
1. Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line.
Verdelli D; Nobili L; Todoerti K; Mosca L; Fabris S; D'Anca M; Pellegrino E; Piva R; Inghirami G; Capelli C; Introna M; Baldini L; Chiaramonte R; Lombardi L; Neri A
Genes Chromosomes Cancer; 2014 Feb; 53(2):154-67. PubMed ID: 24327544
[TBL] [Abstract][Full Text] [Related]
2. Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Park J; Ahn KS; Bae EK; Kim BS; Kim BK; Lee YY; Yoon SS
Anticancer Drugs; 2008 Sep; 19(8):777-82. PubMed ID: 18690088
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
4. Simultaneous inhibition of the constitutively activated nuclear factor kappaB and of the interleukin-6 pathways is necessary and sufficient to completely overcome apoptosis resistance of human U266 myeloma cells.
Malara N; Focà D; Casadonte F; Sesto MF; Macrina L; Santoro L; Scaramuzzino M; Terracciano R; Savino R
Cell Cycle; 2008 Oct; 7(20):3235-45. PubMed ID: 18931595
[TBL] [Abstract][Full Text] [Related]
5. Decursin chemosensitizes human multiple myeloma cells through inhibition of STAT3 signaling pathway.
Kim HJ; Kim SM; Park KR; Jang HJ; Na YS; Ahn KS; Kim SH; Ahn KS
Cancer Lett; 2011 Feb; 301(1):29-37. PubMed ID: 21122982
[TBL] [Abstract][Full Text] [Related]
6. Canonical nuclear factor kappaB pathway inhibition blocks myeloma cell growth and induces apoptosis in strong synergy with TRAIL.
Romagnoli M; Desplanques G; Maïga S; Legouill S; Dreano M; Bataille R; Barillé-Nion S
Clin Cancer Res; 2007 Oct; 13(20):6010-8. PubMed ID: 17947462
[TBL] [Abstract][Full Text] [Related]
7. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors.
Jourdan M; Mahtouk K; Veyrune JL; Couderc G; Fiol G; Redal N; Duperray C; De Vos J; Klein B
Eur Cytokine Netw; 2005; 16(1):57-64. PubMed ID: 15809207
[TBL] [Abstract][Full Text] [Related]
8. Cyclophilins contribute to Stat3 signaling and survival of multiple myeloma cells.
Bauer K; Kretzschmar AK; Cvijic H; Blumert C; Löffler D; Brocke-Heidrich K; Schiene-Fischer C; Fischer G; Sinz A; Clevenger CV; Horn F
Oncogene; 2009 Aug; 28(31):2784-95. PubMed ID: 19503092
[TBL] [Abstract][Full Text] [Related]
9. Molecular and biological characterization of three novel interleukin-6-dependent human myeloma cell lines.
Verdelli D; Mattioli M; Fabris S; Nobili L; Intini D; Guerneri S; Todoerti K; Zanella A; Deliliers GL; Lombardi L; Neri A
Haematologica; 2005 Nov; 90(11):1541-8. PubMed ID: 16266902
[TBL] [Abstract][Full Text] [Related]
10. NF-κB localization in multiple myeloma plasma cells and mesenchymal cells.
Conticello C; Giuffrida R; Adamo L; Anastasi G; Martinetti D; Salomone E; Colarossi C; Amato G; Gorgone A; Romano A; Iannolo G; De Maria R; Giustolisi R; Gulisano M; Di Raimondo F
Leuk Res; 2011 Jan; 35(1):52-60. PubMed ID: 20674018
[TBL] [Abstract][Full Text] [Related]
11. NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells.
Que W; Li S; Chen J
Mol Med Rep; 2013 May; 7(5):1641-5. PubMed ID: 23545701
[TBL] [Abstract][Full Text] [Related]
12. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
Lin H; Kolosenko I; Björklund AC; Protsyuk D; Österborg A; Grandér D; Tamm KP
Exp Cell Res; 2013 Mar; 319(5):600-11. PubMed ID: 23246572
[TBL] [Abstract][Full Text] [Related]
13. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications.
Hideshima T; Chauhan D; Schlossman R; Richardson P; Anderson KC
Oncogene; 2001 Jul; 20(33):4519-27. PubMed ID: 11494147
[TBL] [Abstract][Full Text] [Related]
14. The novel JAK inhibitor CYT387 suppresses multiple signalling pathways, prevents proliferation and induces apoptosis in phenotypically diverse myeloma cells.
Monaghan KA; Khong T; Burns CJ; Spencer A
Leukemia; 2011 Dec; 25(12):1891-9. PubMed ID: 21788946
[TBL] [Abstract][Full Text] [Related]
15. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
16. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 6 promotes endometrial cancer growth through an autocrine feedback loop involving ERK-NF-κB signaling pathway.
Che Q; Liu BY; Wang FY; He YY; Lu W; Liao Y; Gu W; Wan XP
Biochem Biophys Res Commun; 2014 Mar; 446(1):167-72. PubMed ID: 24582558
[TBL] [Abstract][Full Text] [Related]
18. Alkylating agents induce activation of NFkappaB in multiple myeloma cells.
Baumann P; Mandl-Weber S; Oduncu F; Schmidmaier R
Leuk Res; 2008 Jul; 32(7):1144-7. PubMed ID: 18083229
[TBL] [Abstract][Full Text] [Related]
19. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
20. The proteasome inhibitor bortezomib acts independently of p53 and induces cell death via apoptosis and mitotic catastrophe in B-cell lymphoma cell lines.
Strauss SJ; Higginbottom K; Jüliger S; Maharaj L; Allen P; Schenkein D; Lister TA; Joel SP
Cancer Res; 2007 Mar; 67(6):2783-90. PubMed ID: 17363600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
